Navigation Links
HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy

The disease burden of diabetes continues to grow and currently affects more that 18 million Americans and their families. These data emphasize a need for alternative diabetes therapies with earlier more physiologic use of insulin.//

The delivery of insulin by the lung may provide an attractive alternative for many patients with diabetes. However, alternative insulin delivery systems must meet certain pharmacokinetic and glucodynamic requirements to reach maximum utility. Specifically, the dose-response characteristics of inhaled insulin should be similar to those of injectable insulins, like human regular insulin or fast-acting insulin analogs such as insulin lispro. A recent study, published in the October issue of Diabetes Care, evaluated the key performance features of a novel inhaled insulin delivery system -- human insulin inhalation powder (HIIP) -- based on AIR particle technology and its relative biopotency compared with subcutaneous (SC) insulin lispro.

The researchers enrolled 20 healthy, nonsmoking, male or female subjects (aged 29.6 years, BMI 23.2 kg/m2) with normal forced vital capacity and forced expiratory volume in an open-label, randomized, seven-period, euglycemic glucose clamp, cross-over trial. Each subject received up to 4 single doses of HIIP and 3 doses of SC lispro from 5 to 18 days apart.

HIIP demonstrated a similar rapid onset but an extended time exposure and a prolonged duration of effect compared with SC lispro. While the time-action profile was longer for HIIP than for SC lispro, both treatments showed rapid initial absorption and similar overall PK exposure and GD effect.

Remarkably, in the current study not a single episode of cough was registered, suggesting an excellent tolerability of the inhaled insulin when formulated by the AIR particle technology. However, the authors warn that this result needs to be confirmed in much larger phase 3 trials. Taken together, these results suppor t the potential utility of inhaled insulin as an alternative to insulin injections. Because the fear of injections is a frequent cause for delaying appropriate care in patients with type 2 diabetes, inhaled insulin may provide a treatment that delivers effective doses of insulin in a less threatening, more satisfying manner, potentially resulting in improved patient compliance and better outcomes.
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: